<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017053134262N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-08-07</date_registration>
      <primary_sponsor>Dr behzad sharif makhmal zadeh</primary_sponsor>
      <public_title>The effect of topical formulation containing egg whites on healing of second degree wound in burn patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of topical formulation containing egg whites on healing of second degree wound in burn patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-06-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/26222</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>burn.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: Second degree ophthalmic ulcers remain intact and remain intact in the second grade wound, which are usually blisters, after removing the blisters and dead tissues, and after daily rinsing with normal saline, is exposed to air for 5 minutes to dry. Then, 1% silver sulfadiazine silver ointment is placed on the wound by a sterile abscess of 5 mm size. After 1 hour, without wound healing in the intervention group, a sterile abscess of 5 mm formulation Place the egg white on the wound and dressing. Intervention 2: Control group: The second degree otitis wounds remained completely intact and in the second grade wound, which was usually blotched, after removing the blisters and dead tissues, and after daily washing with normal saline, is exposed to air for 5 minutes to dry. Then, 1% silver silver sulfadiazine ointment is placed on the wound by a sterile abscess of 5 mm size, and after 1 hour, without wound wound in the control group, a sterile abscess of 5 mm We take the placebo on the wound and dressing.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>hadis ashrafizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</address>
        <city>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+216 133738255</telephone>
        <email>ashrafizadeh.h1993@gmail.comashrafizadeh.h@ajums.ac.irashrafizadeh.h@yahoo.com</email>
        <affiliation>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>simin jahani/ hadis ashrafizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</address>
        <city>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>00</telephone>
        <email>jahanisimin@yahoo.comashrafizadeh.h1993@gmail.com</email>
        <affiliation>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Second degree burns confirmed by the doctor; The age is between 18-60 years; burn percentage is less than 15 percent; It is not more than 6 hours from the time of the burn until it enters the research; Areas (face, genitals and perineum) are not included in the study due to the sensitivity of these areas; The amount of hemoglobin and total protein is in the normal range. The normal range of hemoglobin (the Ba18-14 in men and in women 16-12 grams per deciliter) and total protein (8.7 to 6.6 grams per deciliter); The patient's wound is not impregnated with contaminants; Before entering the study samples of any substance other than potable water is not used on wounds; Before entering the study, there is no sign of infection with different parts of the body; underlying immune deficiency diseases such as diabetes, cancer, AIDS, hypertension, malnutrition, etc. is not; The patient is not known to have a skin allergy; is able to respond to questions. &#13;
Exclusion criteria: During the study, patients need to use immunosuppressive drugs, steroid drugs, chemotherapy drugs and radiation therapy; If there is any indication that an infected burn wounds treated. Any of these symptoms (edema in the area burned along with induration and inflammation of the edges of the wound, discoloration wound burned to dark red, brown, purple, black, presence of purulent discharge, foul-smelling, green and abundant, fever, during the course of treatment) in treated infected wounds and were removed from the sample study and treatment under doctor's supervision changes.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>949</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>949</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Second degree ophthalmic ulcers remain intact and remain intact in the second grade wound, which are usually blisters, after removing the blisters and dead tissues, and after daily rinsing with normal saline, is exposed to air for 5 minutes to dry. Then, 1% silver sulfadiazine silver ointment is placed on the wound by a sterile abscess of 5 mm size. After 1 hour, without wound healing in the intervention group, a sterile abscess of 5 mm formulation Place the egg white on the wound and dressing.</i_keyword>
      <i_keyword>Control group: The second degree otitis wounds remained completely intact and in the second grade wound, which was usually blotched, after removing the blisters and dead tissues, and after daily washing with normal saline, is exposed to air for 5 minutes to dry. Then, 1% silver silver sulfadiazine ointment is placed on the wound by a sterile abscess of 5 mm size, and after 1 hour, without wound wound in the control group, a sterile abscess of 5 mm We take the placebo on the wound and dressing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Burn wound. Timepoint: The first day / seven days / fifteenth day. Method of measurement: To measure wound plastic tape will be used, which is accurate to about 1: 1000 is. The admission to the clinic (first day) and during treatment seventh day and the fifteenth day, the extent of the wound by contact with a tape measure and guide the measurement of transparent measurement and the basis Length Width expressed, and Jensen wound assessment tool Bts- using parameters that are related to the extent of burn wound, the wound (ulcer depth), the edge of the wound, the destruction of underlying tissue, necrotic tissue, necrotic tissue, exudate, the exudate, color of the skin around the wound, peripheral tissue induration, edema peripheral tissues, tissue granulation and epithelialization by the researchers analyzed tissue M And according to points earned from it will be examined wound healing.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id>-</sec_id>
        <issuing_authority>-</issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dr behzad sharif makhmal zadeh</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-05-02</approval_date>
        <contact_name>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.</contact_name>
        <contact_address>Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran. Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
